长春高新：注射用GenSci136境内生产药品注册临床试验申请获受理

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. ("Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the clinical trial application of its injectable GenSci136, aimed at treating Immunoglobulin A Nephropathy (IgAN) [1] Group 1 - The clinical trial application for GenSci136 has been accepted, indicating progress in the drug development process [1] - The targeted indication for GenSci136 is Immunoglobulin A Nephropathy (IgAN), a significant condition affecting kidney function [1]